Oui Therapeutics
New Haven, US · 3 known investors
Oui Therapeutics develops prescription digital therapeutics aimed at suicide prevention, including what it describes as the first digital therapeutic for suicide, currently in clinical trials. The company works with digital therapy and suicide experts to address suicidal behavior.
Investors · 3
Non-dilutive funding · 6 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase IISTTR | 2023 | $766.5K |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2023 | $375.3K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2022 | $659.5K |
| National Institutes of Health (NIH)National Institutes of Health | Phase IISTTR | 2021 | $3M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2021 | $399K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2020 | $481K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Oui Therapeutics do?
- Oui Therapeutics develops prescription digital therapeutics aimed at suicide prevention, including what it describes as the first digital therapeutic for suicide, currently in clinical trials. The company works with digital therapy and suicide experts to address suicidal behavior.
- Who are Oui Therapeutics's investors?
- Oui Therapeutics's investors include CU Healthcare Innovation Fund, CVS Health Ventures, Flare Capital Partners.
- Where is Oui Therapeutics headquartered?
- Oui Therapeutics is headquartered in New Haven, US.